BridgeBio Corp (BBIO) Enterprise Value to EBITDA Ratio

The EV/EBITDA multiple for capital-intensive businesses visualizes the efficiency of the decentralized development approach at BridgeBio Pharma, Inc. (BBIO). The transition to active drug sales optimizes research costs, thereby increasing margins. However, success remains dependent on regulatory approvals and access to capital. The value of 0.00 represents the latest metric reading, helping to determine trend inertia and the reliability of the current price trajectory.

BridgeBio Pharma - BBIO Company Value to EBITDA (period 11/23/2025 - 11/11/2026)

Comprehensive metric breakdowns and analytics for bridgebio.com (BBIO)

- current price and projected stock value:

Stock Price BridgeBio Pharma Inc|BBIO - Analyst Median Target

- market capitalization details:

Market Valuation BridgeBio Corp|BBIO - Full Business Value

- business book valuation details:

Book Value per Share BridgeBio|BBIO - Total Stockholders' Equity|Market Capitalization to Book Value Ratio bridgebio.com|BBIO - Total Business Assets

- debt burden and liquidity indicators:

- financial results and valuation multiples details:

BBIO - Final Profit|Expected Profit BridgeBio Pharma, Inc.|BBIO - Price to Earnings Ratio|Forward P/E Multiple BridgeBio Pharma, Inc.|BBIO - PEG Multiple|EV/EBITDA Multiple BridgeBio Corp|BBIO - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months BridgeBio|BBIO - Earnings per share for the trailing year|Quarterly EPS earnings growth bridgebio.com|BBIO - Expected net earnings per share growth this year|Earnings growth forecast for next year BridgeBio Pharma, Inc.

Fundamental valuation:BridgeBio Pharma Inc BBIO

A conservative approach to analyzing BridgeBio Pharma, Inc. (BBIO) requires accounting for debt load and tax liabilities. This metric compares the total enterprise value with operating profit before depreciation and amortization, revealing the real value of assets. By analyzing the historical EV/EBITDA value, an investor can identify capital consolidation phases prior to new growth spurts. For the decentralized R&D model of BridgeBio Pharma, Inc. (BBIO), this ratio confirms the investment efficiency in autonomous teams of geneticists.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BGM Group (BGM)|COGT (Cogent Bio) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XERS (Xeris Pharma)|Enterprise Value to EBITDA Ratio KROS (Keros Therapeutics)|ARCT (arcturusrx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eton Pharmaceuticals, Inc. ETON|KMDA (Kamada Ltd) - Company Value to Operating Income Before Depreciation Ratio|Fulcrum Tx - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ABEO (Abeona Therapeutics)|MREO: EV/EBITDA Multiple|protalix.com (PLX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pliant Therapeutics Inc|APLT: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rein Therapeutics, Inc. (RNTX)|Enterprise Value to EBITDA Ratio gelteq.com GELS|EV/EBITDA Multiple AYTU (Aytu BioPharma)|EV/EBITDA Multiple Chemomab Therapeutics Ltd CMMB|SRx Health - EV/EBITDA Multiple|PLRZ: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|zentaris.com (AEZS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Cyclo Therapeutics, Inc - Business Value to Operating Income Before Depreciation|INZY (Inozyme Pharma Inc.) - EV/EBITDA Multiple|reneopharma.com (RPHM) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CSCI